Support

Lorem ipsum dolor sit amet:

24h / 365days

We offer support for our customers

Mon - Fri 8:00am - 5:00pm (GMT +1)

Get in touch

Cybersteel Inc.
376-293 City Road, Suite 600
San Francisco, CA 94102

Have any questions?
+44 1234 567 890

Drop us a line
info@yourdomain.com

About us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec.

EN
Have any Questions? +01 123 444 555

Improving the care of patients with non-alcoholic fatty liver inflammation.

Approximately 12 million people have non-alcoholic fatty liver disease (NAFLD) in Germany. NAFLD is primarily caused by an unhealthy lifestyle which is characterised by too little exercise and excessive caloric intake. In around a third of patients, non-alcoholic fatty liver disease develops into non-alcoholic steatohepatitis (NASH). If the disease progresses undetected and thus untreated, it can lead to serious health complications such as liver cancer, cirrhosis and liver failure.

Patients with non-alcoholic fatty liver disease often have additional metabolic disorders and diseases that in themselves pose a large hazard to health and carry an increased risk of mortality. These associated conditions include, in particular, obesity, type 2 diabetes mellitus and coronary heart disease.

Thus, it is imperative that patients with non-alcoholic fatty liver disease receive intensive multidisciplinary medical care. Even if the focus of liver disease is on the treatment of the liver, any existing comorbidities must be integrated in the patient’s diagnosis and course of treatment, from the diagnosis to therapy and monitoring.

Non-alcoholic fatty liver disease is not a new disease, yet routine care data suggest that it has been significantly underdiagnosed, and many patients find their way to the doctor late and only in advanced stages. However, in view of its prevalence and the resources in the health care system, the discussion about adequate care for these patients is gaining momentum.

In order to establish interdisciplinary and holistic care concepts for fatty liver disease patients (with multiple morbidities), not only must the medical professional societies work closely together, but healthcare policy in particular must also create legal framework conditions that allow for the best possible medical care structure.

This position paper is intended to draw the attention of political actors in the field of healthcare to the existing gaps in care and thus to initiate the healthcare policy discourse. Together with well-known experts and the support of Intercept Pharma Deutschland GmbH, Kautz5 gUG has drafted a political position paper. The coordination office is provided by the Berlin agency Miller & Meier Consulting GmbH.

Go back

Copyright 2021 Kautz⁵. All Rights Reserved.